Huang Qiong-Zhu, Liu Xiao-Meng, Huang Guo-Quan, Wang Li-Juan, Zheng Yu-Jie, Chen Xin-Cheng, Liu Li-Bin, Chen Zhou
Department of Endocrinology, the 476 th Hospital of People's Liberation Army, Fuzhou 350002, China.
College of Pharmacy, Fujian Medical University, Fuzhou 350122.
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2017 Feb 8;33(2):128-131. doi: 10.12047/j.cjap.5466.2017.033.
To investigate the protective effect of exenatide (Ex) on the renal injury in streptozotocin-induced diabetic rats.
Sprague-Dawley rats were randomly divided into 2 groups:normal control group (NC group, =8) and model group. Model group was injected with low dose of streptozotocin (30 mg·kg) after the rats were fed with high fat and high glucose diet for 4 weeks. Seventy-two hours later, rats of blood glucose level ≥ 16.7 mmol·L were divided into diabetes mellitus group (DM, =10) and two exenatide-treated groups (Ex groups,3 or 6g·kg, =8). Ex groups subcutaneously injected with exenatide for 12 weeks, but NC group and DM group were injected with the same volume of solvent. Changes in glycolipid metabolism and renal function such as serum creatinine (Scr), urine creatinine (Ucr), blood urea nitrogen (BUN), 24 hour urine micro-albumin (24 h UMA)in the 4 groups of rats were determined and creatinine clearance rate (Ccr) were calculated. Renal oxidative stress parameters such as superoxide dismutase (SOD), malondialdehyde(MDA), glutathione per-oxidase (GSH-Px) were measured. Hematoxylin-eosin (HE) staining was used to examine pathological morphology in the renal tissues and ELISA was performed to determine the level of advanced glycation end products(AGEs), the glycosylation end product in renal tissues.
Compared to the DM group,glycolipid metabolic abnormalities in the exenatide-treated groups were significantly ameliorated with lower levels of blood glucose,HbAlc, cholesterol and triglyceride ( < 0.05). The renal function index was markedly improved ( < 0.05) with Ccr reduced, indicating a high glomerular filtration status. Meanwhile, exenatide treatment improved the diabetes-induced pathological changes in renal morphology, substantially increased the activities of SOD and GSH-Px, and reduced the levels of MDA and AGEs.
Exe-natide has the renal protective effect probably by the mechanisms of inhibition of AGEs production and reduction of oxidative stress in the renal tissues of diabetic rats.
探讨艾塞那肽(Ex)对链脲佐菌素诱导的糖尿病大鼠肾损伤的保护作用。
将Sprague-Dawley大鼠随机分为2组:正常对照组(NC组,n = 8)和模型组。模型组大鼠高脂高糖饮食4周后,注射低剂量链脲佐菌素(30 mg·kg)。72小时后,血糖水平≥16.7 mmol·L的大鼠分为糖尿病组(DM,n = 10)和两个艾塞那肽治疗组(Ex组,3或6 μg·kg,n = 8)。Ex组皮下注射艾塞那肽12周,而NC组和DM组注射相同体积的溶剂。测定4组大鼠糖脂代谢和肾功能变化,如血清肌酐(Scr)、尿肌酐(Ucr)、血尿素氮(BUN)、24小时尿微量白蛋白(24 h UMA),并计算肌酐清除率(Ccr)。检测肾氧化应激参数,如超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)。采用苏木精-伊红(HE)染色观察肾组织病理形态,采用酶联免疫吸附测定(ELISA)法检测肾组织中晚期糖基化终末产物(AGEs)水平,即糖基化终末产物。
与DM组相比,艾塞那肽治疗组糖脂代谢异常明显改善,血糖、糖化血红蛋白(HbAlc)、胆固醇和甘油三酯水平降低(P < 0.05)。肾功能指标明显改善(P < 0.05),Ccr降低,提示肾小球滤过状态良好。同时,艾塞那肽治疗改善了糖尿病引起的肾形态病理变化,显著提高了SOD和GSH-Px活性,降低了MDA和AGEs水平。
艾塞那肽可能通过抑制糖尿病大鼠肾组织中AGEs生成和降低氧化应激的机制发挥肾保护作用。